Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome

Cynthia Bodkin; Robert M Pascuzzi

doi:10.1016/j.ncl.2020.09.007

Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome

Neurol Clin. 2021 Feb;39(1):133-146. doi: 10.1016/j.ncl.2020.09.007. Epub 2020 Nov 7.

Authors

Cynthia Bodkin¹, Robert M Pascuzzi²

Affiliations

¹ Clinical Neurology, Physical Medical Rehabilitation, Indiana University School of Medicine, Indiana University Health, Indianapolis, IN, USA. Electronic address: cbodkin@iu.edu.
² Neurology Department, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana, USA.

PMID: 33223079
DOI: 10.1016/j.ncl.2020.09.007

Abstract

Myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weakness and include autoimmune, toxic, and genetic conditions. Adults with NMJ disorders are most often antibody mediated, with MG being the most common, having a prevalence of approximately 1 in 10,000, and with women being affected about twice as often as men. This article focuses on advances in management of autoimmune MG and LEMS.

Keywords: Complement inhibitor; Lambert Eaton myasthenic syndrome; Myasthenia gravis; Thymectomy; Weakness.

Publication types

Review

MeSH terms

Adult
Female
Humans
Lambert-Eaton Myasthenic Syndrome / diagnosis
Lambert-Eaton Myasthenic Syndrome / therapy*
Male
Myasthenia Gravis / diagnosis
Myasthenia Gravis / therapy*